Virosomes as new carrier system for cancer vaccines by Schwaninger, Ruth et al.
ORIGINAL ARTICLE
Ruth Schwaninger Æ Ernst Waelti Æ Paul Zajac
Antoinette Wetterwald Æ Dominique Mueller
Claude D. Gimmi
Virosomes as new carrier system for cancer vaccines
Received: 19 December 2003 / Accepted: 22 March 2004 / Published online: 5 June 2004
 Springer-Verlag 2004
Abstract HER-2/neu, a tumor-associated antigen
(TAAg), plays a critical role in oncogenesis of various
tumor types, and its selective overexpression bymalignant
tumor cells makes it an ideal target for immunotherapy.A
prerequisite for clinical vaccines is the construction of safe
and highly immunogenic reagents able to generate eﬃ-
cient immune responses against TAAg. Previous protein
vaccines, consisting of the extracellular domain of HER-
2/neu (pNeuECD), were shown to elicit an immune response
that did not provide protection from transplantable
tumors expressing HER-2/neu. Here we showed that
virosomes, which consist of reconstituted viral envelopes
without viral genetic material, can act as a carrier and an
adjuvant for a truncated protein pNeuECD . Mice vacci-
nated with pNeuECD either encapsulated in virosomes or
bound to the virosomal membrane (Vir-pNeuECD), gen-
erated rNeu-speciﬁc humoral and cytotoxic immune
responses. In addition, Vir-pNeuECD induced signiﬁcant
tumor rejection and additionally did not lead to delayed
tumor formation when compared with free pNeuECD in
complete Freund’s adjuvant. There was no diﬀerence
between the virosomal constructs. Taken together these
results suggest that virosomes, as clinically approved safe
vaccines, can be used to elicit both humoral and cell-
mediated responses against TAAg and induce
tumor rejection. Our model is providing important pre-
clinical data to design human vaccination trials for
patientswith tumors overexpressingHER-2/neu, either as
a primary vaccination or as a boost in combination with
other vaccines in a context of an adjuvant treatment plan.
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Introduction
HER-2/neu, a transmembrane tyrosine kinase, has been
linked to the malignant transformation of human
breast, prostate, lung, and colorectal tumors [1–4].
HER-2/neu has become an attractive target and rec-
ognized antigen for immunotherapy, as both detectable
HER-2/neu–speciﬁc IgG antibodies and cytotoxic T
cell (CTL) responses have been demonstrated in pa-
tients with cancer overexpressing HER-2/neu, thus
indicating that self-tolerance has been circumvented [5,
6]. A prerequisite for clinical applications of immuno-
therapy or cancer vaccines is the construction of highly
immunogenic reagents able to eﬃciently generate im-
mune responses against tumor-associated antigens
(TAAgs). Replication incompetent viral vectors, devel-
oped to express TAAgs, have been demonstrated to be
safe and potent in generating a humoral and cellular
immune response [7, 8]. However, despite the superi-
ority of viral vaccines there is an increasing safety
concern when oncogenic DNA inserts are involved. In
contrast, virosomes represent an attractive new delivery
system to antigen-presenting cells (APCs) based on
their unique targeting and membrane fusion properties
[9]. Virosomes are reconstituted inﬂuenza viral enve-
lopes, which lack the genetic material but retain the cell
entry and membrane fusion characteristics of the virus
they are derived from [10]. By virtue of this membrane
fusion activity they can introduce exogenous antigens
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directly into the cytosols of APCs, thus accessing the
MHC class I pathway without de novo protein syn-
thesis [11–13]. In addition to facilitating the uptake of
exogenous proteins, virosomes have also been shown to
act as immunoadjuvants and to induce an eﬃcient
humoral and cytotoxic immune response in primed
mice against viral antigens [14].
In our study, we used virosomes as an immunoad-
juvant and new antigen carrier system to investigate the
immune response and tumor rejection capacity of vac-
cinated mice in comparison to protein and viral vac-
cines. We chose HER-2/neu as a model tumor antigen
and used the extracellular domain of HER-2/neu protein
(pNeuECD), ﬁrst to avoid the restriction of immuno-
dominant epitopes and second to generate durable
immunity by immunizing with putative T-helper epi-
topes. Our results showed that virosomes could be used
as carrier and immunoadjuvant for a truncated pNeuECD
protein encapsulated or bound to diﬀerent virosomal
constructs (Vir-pNeuECD). Vir-pNeuECD protected a sig-
niﬁcant number of mice from tumor formation com-
pared with free pNeuECD + complete Freund’s adjuvant
(CFA) and this protection correlated with the induction
of cytotoxic and humoral immune responses. This paper
supports the use of virosomes as a new and safe carrier
system and adjuvant for cancer vaccines.
Material and methods
Chemicals
N-Hydroxysuccinimide ester of palmitic acid (NHSP),
N-(1-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammoni-
um methyl sulfate (DOTAP), and 3-sn-phosphatidyl-
choline (PC; Sigma, St Louis, MO, USA).
Mice
Female virgin MMTV/r-Neu FVB mice (H-2q) trans-
genic for the rat neu protein (rNeu-TG) and FVB/N
mice (H2q) were purchased from Charles River, Ger-
many. Laboratory animal care was in accordance with
institutional guidelines.
Cell lines
IT22 3T3 (H-2q) ﬁbroblasts were cotransfected with a
SV2-Neo-SP65 and a pBR322-rNeu plasmid. G418-re-
sistent rNeu+ clones (IT22-neu) were selected for their
rNeu expression by indirect immunoﬂuorescence by
FACS. The syngeneic rNeu+ (H-2q) breast cancer cell
line NF9006 derived from a rNeu-TG mouse and the
syngeneic rNeu (H-2q) breast cancer cell line K635
derived from a c-myc-TG mouse have previously been
described [15].
Ampliﬁcation and cloning of the extracellular
part of HER-2/neu (NeuECD)
TheDNA sequence coding for the extracellular part of rat
HER-2/neu (corresponding to amino acid 1-655) was
ampliﬁed by PCR. The following primers were
used: 5¢-AATTCGCAATGATCATCATGGAGCTG-3¢
(5¢ primer) and 5¢-GCCAGCCCGGTGACATAA-3¢
(3¢ primer) using pSV2neuN [16] as template. The 3¢ pri-
mer contained a stop codon, so that only the extracellular
part of HER-2/neu was expressed. The fragment was
cloned into pVAX1 (Invitrogen, Cat: V260-20; Gronin-
gen, Netherland), ampliﬁed, puriﬁed, and used as a vac-
cine, either as free DNA or packed into virosomes.
Immunohistochemistry
Cytospins of NF9006 and Vir-DNA-NeuECD infected
COS cells were incubated with a mouse anti-rat HER-2/
neu (7.16.4, Oncogene Science) Ab diluted in PBS and
goat serum. After incubation with biotin-conjugated
goat antimouse Ab (Dako, Copenhagen, Denmark),
reactivities were detected using an avidin-biotin complex
(Dako) and Newfuchsin substrate (Sigma) according to
manufacturer’s instructions.
Expression plasmid construction, protein expression,
and isolation/puriﬁcation of the pNeuECD
cDNA encoding the extracellular part of rat Neu
(NeuECD) was ligated into MCS of the pBADHisB
expression vector (Invitrogen). For protein expression
pBADHisB-NeuECD was grown in Escherichia coli to an
OD600 of 0.5, protein expression was induced with
L-arabinose at a ﬁnal concentration of 0.2% for 3 h.
Cells were then pelleted and sonicated, and pNeuECD was
isolated and puriﬁed from the collected lysates by
quantitative SDS PAGE with Model 491 Prep Cell (Bio-
Rad Laboratories, Glattbrugg, Switzerland) according
to the manufacturer’s instructions. Puriﬁed fractions
were collected and analyzed in a Western blot.
Fatty acylation of the pNeuECD
To attach the antigen (pNeuECD) to the surface of the
virosomal lipid bilayer, pNeuECD was covalently coupled
to palmitic acid using a fatty acylation reaction [17].
Preparation of DNA plasmid-virosome complexes
(Vir-DNA-NeuECD)
Plasmid pVAX1-NeuECD was encapsulated in virosomes
as follows. A 1.5-ml solution of plasmid (590 lg) was
added to 3 ml of HBS (Hepes, 20 mmol/l; NaCl,
150 mmol/l, pH 7.4) and mixed with 1.5 ml of HBS
1006
containing 2.95-mg DOTAP and then ultrasonicated.
Furthermore, inﬂuenza virosomes containing 70%
DOTAP in the lipid membrane were prepared as de-
scribed previously [18]. DNA plasmid-virosome com-
plexes were prepared by mixing DOTAP-encapsulated
plasmid liposomes (6 ml) with 2.8 ml of DOTAP-viro-
somes, and subsequently fused by ultrasonication at
room temperature. The resulting solution contained
66.2 lg plasmid/ml.
Preparation of Vir-pNeuECD mem
Hemagglutinin (HA) from the A/Singapore/6/86 strain
of inﬂuenza virus was isolated as previously described
[18, 19]. Supernatant containing solubilized HA trimer
(3.9 mg/ml) in 0.01 M E12E8 was used for the produc-
tion of virosomes. PC (112 mg) in chloroform was ad-
ded to a round-bottomed ﬂask, and the chloroform was
evaporated by a rotary evaporator. The supernatant
(7.1 ml containing 28 mg HA) and 11 ml of palmitoyl
pNeuECD were added to the ﬂask. The PC ﬁlm was sol-
ubilized under gentle shaking. The mixture was brieﬂy
treated by ultrasonication and then ﬁltered through a
0.2-lm ﬁlter. The detergent of the resulting solution was
removed by extraction with sterile Biobeads SM-2 (Bio-
Rad, Richmond, CA, USA). The content of palmitoyl
pNeuECD was veriﬁed by Western blot (see below).
Preparation of Vir-pNeuECDenc
Vir-pNeuECDenc was prepared as described above with
the exception that the antigen pNeuECD was added to the
mixture. After formation of virosomes, nonencapsulated
material was removed by size exclusion chromatography
on a High Load Superdex 200 column (Pharmacia,
Uppsala, Sweden). The content of pNeuECD was deter-
mined by Western blot as mentioned below.
Western blot analysis
The pNeuECD in the diﬀerent preparations was identiﬁed
using anti-6xHis monoclonal antibody (Clontech Lab-
oratories, Palo Alto, CA, USA) and sheep antimouse
AP-conjugated Ig (Chemicon, Temecula, CA, USA) as
secondary antibody. Content of pNeuECD was estimated
using QuantiScan (Biosoft, Cambridge, UK).
Generation and inactivation of recombinant vaccinia
virus vector, rVV-NeuECD
The domain of NeuECD was ﬁrst cloned into a vaccinia
shuttle vector (generous gift from Dr K.Tsung, San
Francisco, CA, USA) enabling insertion and transcrip-
tion in the viral genome. The insert was ﬂanked by two
viral sequences enabling homologous recombination in
the A56R loci (hemagglutinin-nonessential gene) of
vaccinia virus (Copenhagen strain). A clonal re-
combinant virus was obtained after several rounds of
plaque isolation (using transient gpt selection [20]) on
CV-1 cells (ATCC CCL70). Several separately isolated
clones were PCR screened and one positive recombinant
was then ampliﬁed and concentrated on 36% sucrose
cushions. Viral solutions were titered on CV-1 cells.
Virus replication was inactivated by a limited treatment
with 1 lg/ml psoralen (Trioxsalen; Calbiochem, Cam-
bridge, MA, USA) for 10 min at room temperature
followed by 8 min exposure to 354-nm long-wave UV
(Stratalinker; Stratagene, La Jolla, CA, USA) as de-
scribed previously [8, 21].
FACS analysis for Neu expression on cell line
and rNeu-speciﬁc antibody levels in serum
Syngeneic ﬁbroblast cells (IT22-neu) were analyzed for
their rNeu-expression as previously described [22].
RNeu+ NF9006 cells (0.5·106) were used to determine
rNeu-speciﬁc antibodies in sera of mice after diﬀerent
vaccines. The method used and cell analysis for ﬂuo-
rescence on a FACScan has been previously described
[23].
Vaccination protocols
Vaccination/boost studies were performed in female
virgin FVB mice as previously described [15] with the
following vaccines: 1·108 pfu recombinant vaccinia
virus (rVV) encoding for NeuECD (rVV-NeuECD) i.p., or
1·108 pfu wild type vaccinia virus (WT-VV) i.p.,
or 20 lg of plasmid DNA pVAX1 (fDNA) i.m. or s.c.,
or 20 lg of pVAX1 encoding for NeuECD (fDNA-
NeuECD) i.m. or s.c., or 20 lg of fDNA-NeuECD
encapsulated in virosomes (Vir-DNA-NeuECD) i.p.
In other sets of experiments the following vaccines were
used: 20 lg of free pNeuECD with 50 ll of CFA adju-
vant (N-acetylglycosaminyl-(b1-4)-N-acetylmuramyl-
L-alanyl-D- isoglutamine; Gerbu, Gaiberg, Germany)
s.c., or 20 lg of pNeuECD encapsulated in virosomes (Vir-
pNeuECD enc), or 20 lg of pNeuECD bound to virosome
membranes (Vir-pNeuECD mem), or a mixture of the two
(Vir-pNeuECD enc/mem), or empty virosomes all injected
i.p. Two weeks after boost, mice were challenged in the
back by a subcutaneous (s.c.) injection of 0.5·106 rNeu+
tumor cells. Tumor formation and size was assessed
every 3 days using a calibrator. The tumor progression
was monitored at the challenge site for 8 weeks.
CTL generation
Spleen cells (at 5·105 cells/well) were restimulated in
vitro on irradiated IT22-neu cells seeded at 1.5·105 cells/
well in 24-well plates. Spleen cells were cocultured for
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5 days, then used for the cytotoxicity assay described
below.
XTT-based cytotoxicity assay
Lytic function of restimulated eﬀector cells against IT22-
neu and IT22 target cells was evaluated at diﬀerent
eﬀector to target ratios (E/T 100:1–0.3:1) in triplicate
samples. After overnight coincubation of eﬀector and
target cells, 50 ll of XTT-solution (Roche Diagnostics,
Rotkreuz, Switzerland) was added to each well accord-
ing to the manufacturer’s instructions, and absorbance
at 490 nm was evaluated on an ELISA reader (Bio-
Rad). Percentage speciﬁc lysis was calculated for each E/
T ratio as follows:
%Neu-specific killing
¼ %killing of specific targets ðIT22-neuÞ
%killing of unspecific targets ðIT22Þ
ELISA analysis of anti-pNeuECD
Anti-pNeuECD speciﬁc antibodies in the sera of mice were
determined by an ELISA in ﬂat-bottomed plates coated
with pNeuECD in 50-mM carbonate buﬀer (pH 8.5)
overnight. Serum samples were diluted in sample buﬀer
1:25. As a detecting antibody, horseradish peroxidase–
labeled sheep antimouse Ig (Amersham Pharmacia
Biotech, UK) was used at a dilution of 1:1,000. The
reaction was developed by tetramethylbenzidine (TMB)
substrate solution and stopped by the addition of 1-m
H2SO4.
Statistical analysis
All statistical analyses were made using the Mann-
Whitney rank test. For all cases, results were considered
signiﬁcant if p values were <0.05.
Results
RNeu protein is expressed in cells transfected
with plasmid encapsulated virosomes
To evaluate whether plasmid DNA (fDNA) encapsu-
lated in virosomes would result in expression of the
cloned gene and induce protein production, we chose a
plasmid vector containing a strong promoter (CMV) for
optimal expression in mammalian cells and immuno-
stimulatory cytidine-phosphate-guanosine motifs for
increased activation of B cells, T cells, and dendritic cells
[24]. We engineered a fDNA-NeuECD plasmid designed
to express the extracellular domain of rat Neu (NeuECD).
Before testing this plasmid as vaccine in vivo, the protein
expression in transfected COS cells was evaluated in
immunohistochemical analysis. Cells transfected with
fDNA-NeuECD stained strongly when a mouse antibody
(Ab) recognizing an extracellular epitope of rNeu (Ab
7.16.4) was used, whereas no expression could be de-
tected in the same cells when a rabbit antibody recog-
nizing an epitope of the intracytoplasmic part of human/
rat Neu was selected (data not shown). To conﬁrm
rNeuECD protein production in cells transfected with
plasmid DNA-NeuECD encapsulated in virosomes (Vir-
DNA-NeuECD), immunohistochemical staining was
performed on cytospins of Vir-DNA-NeuECD infected
COS cells using again the mouse monoclonal antibody
7.16.4 against rat NeuECD (Fig. 1). The spontaneous
breast tumor cell line NF9006, as control, showed a
strong staining with mAb 7.16.4 (Fig. 1a). COS cells
transfected with Vir-DNA-NeuECD showed a clear
staining for NeuECD protein in the cytoplasm of 20–30%
of these cells using the same mAb 7.16.4 (Fig. 1b). No
staining could be detected in COS cells transfected with
empty virosomes or Vir-DNA (no insert) when the same
antibody was used (Fig. 1c, d). These results conﬁrmed
that cells transfected with plasmid DNA-NeuECD
encapsulated in virosomes were capable of producing
the antigen.
Prophylactic vaccination with fDNA-NeuECD
signiﬁcantly inhibits tumor formation
Virosomes have been used as carriers for the introduc-
tion of nucleic acid into mammalian cells in vitro [18].
To evaluate whether Vir-DNA-NeuECD could be used as
vaccine and increase rejection of a tumor challenge
compared with fDNA-NeuECD, the following experi-
ments were performed: MMTV/r-Neu and/or FVB/N
female mice were vaccinated and boosted with re-
combinant vaccinia virus encoding NeuECD (rVV-
NeuECD), with wild-type vaccinia (WT-VV) as negative
control, with fDNA (no insert), with fDNA-NeuECD, or
with Vir-DNA-NeuECD (as described in ‘‘Material and
methods’’). Two weeks after the boost, mice were chal-
lenged with either the syngeneic rNeu+ (NF9006) or
rNeu (K635) breast cancer cell lines and assessed for
tumor formation at the challenge site. As shown in
Table 1, immunization with fDNA-NeuECD s.c. pro-
tected 11 out of 15 mice from tumor formation (tumor
incidence 4/15). The speciﬁcity of this protection was
conﬁrmed, as fDNA-NeuECD vaccination did not
%lysis ¼ OD ðtarget aloneÞ OD ðtargetþ effectorsÞ  ðeffectors aloneÞ½ 
OD (target alone)
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protect mice from forming tumors after a challenge with
the rNeu syngeneic breast cancer cell line (K635). In
contrast, the immunization with Vir-DNA-NeuECD re-
sulted in a lack of protection, as 13 mice out of 14
developed tumors with NF9006 breast cancer cells. The
injection of Vir-DNA-NeuECD s.c. or i.p. showed no
diﬀerence in tumor rejection. None of the rVV-NeuECD
vaccinated mice developed tumors for an observation
period more than 2 months, whereas all mice vaccinated
with WT-VV and fDNA (no insert), developed tumors
at the challenge site. These results indicated that Vir-
DNA-NeuECD seemed incapable of stimulating tumor
rejection.
Table 1 Vaccination with fDNA but not with Vir-DNA partially
prevents tumor formation. Mice were vaccinated and boosted with
WT-VV i.p., rVV-NeuECD i.p., fDNA s.c., fDNA-NeuECD s.c., Vir-
DNA-NeuECD i.p. Two weeks after the boost, each group was
challenged s.c. with either 0.5·106 Neu+ tumor cells (NF9006) or
0.5·106 Neu tumor cells (K635), and tumor progression was
monitored at the challenge site for 8 weeks. The results combine
four independent experiments
Vaccination Tumor incidence
With rNeu+ challenge With rNeu challenge
rVV-NeuECD 0/13 (0%) 5/7 (71%)
WT-VV 9/9 (100%) 6/6 (100%)
fDNA-NeuECD 4/15 (26%) 5/5 (100%)
fDNA 11/11 (100%) 3/3 (100%)
Vir-DNA-NeuECD 13/14 (92%) n.d.
Fig. 1a–d Expression of rNeuECD on a breast cancer cell line and
transfected COS cells. a Neu+ breast cancer cell line (NF9006); b
COS cells transfected with Vir-DNA-NeuECD; c COS cells
transfected with empty Vir; d COS transfected with Vir-DNA.
(Magniﬁcation a, c, and d: ·280, and b: ·560). Bar is 50 lm
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FDNA-NeuECD, but not Vir-DNA-NeuECD, generates
rNeu-speciﬁc cytotoxic and humoral immune responses
We then examined whether mice vaccinated with fDNA-
NeuECD, either free or encapsulated in virosomes (Vir-
DNA-NeuECD), would generate rNeu-speciﬁc CTLs
and/or anti-rNeu Ab responses. A syngeneic rNeu-po-
sitive IT22 ﬁbroblast cell line was used as target cells in
CTL experiments (see ‘‘Material and methods’’). IT22-
neu expressed signiﬁcant amounts of cell surface rNeu as
monitored by immunoﬂuorescence staining (Fig. 2). No
rNeu expression was detected on IT22 ﬁbroblasts. Also
shown in Fig. 2 is the MHC class I and MHC class II
staining of the two syngeneic ﬁbroblast cell lines. Both
cell lines expressed similar levels of MHC class I and
were negative for MHC class II.
Having demonstrated that vaccination and boost in-
duced tumor rejection in fDNA-NeuECD but not in Vir-
DNA-NeuECD vaccinated mice, rNeu-speciﬁc CTLs were
analyzed in spleen cells of animals vaccinated either with
fDNA-NeuECD, Vir-DNA-NeuECD, fDNA (no insert),
rVV-NeuECD, orWT-VV, using a colorimetric assay with
XTT. As shown in Fig. 3a, the CTL activity was most
eﬀective in mice immunized with rVV-NeuECD, with a 6–
13-fold greater rNeu-speciﬁc lytic activity compared with
mice vaccinated with WT-VV. Spleen cells from mice
immunized with fDNA-NeuECD also developed rNeu-
speciﬁc killing in vitro at diﬀerent eﬀector to target ratios;
however, at a reduced percentage level as mice vaccinated
with rVV-NeuECD. In contrast, there were only back-
ground levels of speciﬁc cell lysis in mice vaccinated with
Vir-DNA-NeuECD, similar tomice vaccinatedwith fDNA
(no insert) and WT-VV.
To determine whether immunization with the above-
mentioned vaccines would induce a rNeu-speciﬁc
humoral immune response, sera of vaccinated and
boosted mice were collected at days 49–56 after the ﬁrst
vaccination. The presence of anti-rNeu antibodies was
assessed by ﬂow cytometry as previously described [23].
As shown in Fig. 3b, sera from mice injected with rVV-
NeuECD showed an impressive level of antibody binding
(mean = 31.8, SEM=8.9). Similarly, an increase of
antibody binding over baseline was noticed in fDNA-
NeuECD vaccinated mice (mean = 22.3, SEM=11.0). In
comparison, mice primed with Vir-DNA-NeuECD pro-
duced no rNeu-speciﬁc IgG (mean = 16.3, SEM=5.0)
similar to sera from mice immunized with fDNA or WT-
VV (both mean = 15.8, SEM=4.2).
Taken together, these results indicated that the dif-
ference in tumor rejection between fDNA-NeuECD and
Vir-DNA-NeuECD correlated with the discrepancy of
the induced cellular and humoral immune responses by
the two vaccines.
Virosomes can act as protein carrier system
and signiﬁcantly increase tumor rejection compared
with free protein
To investigate whether virosomes could be used as car-
rier and adjuvant for protein TAAg, we produced
NeuECD–protein (pNeuECD), using a truncated rNeuECD
protein of 90 kDa and engineered two diﬀerent viroso-
mal constructs; in the ﬁrst construct, pNeuECD
was encapsulated into the lumen of virosomes (Vir-
pNeuECDenc), whereas in the second construct, pNeuECD
was inserted into the lipid bilayer by covalently coupling
pNeuECD to the palmitoyl fatty acid residues
(Vir-pNeuECDmem). In a Western blot analysis the dif-
ferent virosomal constructs demonstrated approxi-
mately the same amount of pNeuECD (data not shown).
We investigated whether vaccination with these
virosomal constructs (Vir-pNeuECDenc, Vir-pNeuECD
mem, or the combination of both Vir-pNeuECDmem/
Fig. 2 FACs analysis of rNeu-
transfected syngeneic IT22
ﬁbroblast cell lines: IT22 were
cotransfected with a control
neomycin vector and with a
vector expressing rNeu (IT22-
neu). IT22 and IT22-neu cell
lines were analyzed for HER-2/
neu cell surface expression by
indirect immunostaining using
the rNeu-speciﬁc mAb (7.16.4)
followed by RPE-conjugated
goat antimouse IgG. For
analysis of MHC class I
expression, the biotin
antimouse H-2Dq/H2Lq
(KH117) and for MHC class II
the biotin antimouse I-Aq
(KH116) were used, followed
by streptavidin-RPE. The dark
shaded area indicates control
staining with RPE-conjugated
goat antimouse IgG or
streptavidin-RPE alone
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enc) would increase tumor rejection compared to free
pNeuECD injected with CFA. Female mice were vacci-
nated and boosted with pNeuECD + CFA or the dif-
ferent virosomal constructs. These vaccines were tested
against rVV-NeuECD and empty Vir as controls.
Rejection of a tumor cell challenge was assessed by
s.c. injection of rNeu+ and rNeu syngeneic breast
cancer cells. As shown in Table 2, all mice vaccinated
with empty Vir developed tumors at the injection site.
They all developed their tumors within 24 days after
tumor injection (range 8–24 days). Within the obser-
vation period of 8 weeks, only 27% (3 out of 11) of
Vir-pNeuECD mem–vaccinated mice and only 30% (3
out of 10) of Vir-pNeuECDmem/enc–vaccinated/boosted
mice had developed tumors. Mice vaccinated with ei-
ther of the Vir-pNeuECD constructs developed an
impressive protection from tumor formation when
compared with mice vaccinated with pNeuECD + CFA,
where 10 mice out of 15 tested formed tumors at the
injection site. Again, these protections were shown to
be rNeu-speciﬁc, as mice challenged with rNeu breast
cancer cells were not protected from tumor formation.
Mice vaccinated with rVV-NeuECD, Vir-p
NeuECDenc,
Vir-pNeuECDmem, or Vir-pNeuECDmem/enc showed no
signiﬁcant diﬀerence in their time to tumor formation
(p<0.5; Fig. 4a). Thus, prophylactic vaccination with
pNeuECD in virosomes (Vir-pNeuECDmem/enc, Vir-
pNeuECDmem, Vir-pNeuECDenc) signiﬁcantly prevented
the development of tumors at the injection site, in
comparison to mice vaccinated with empty Vir as
controls (p<0.02, by Mann–Whitney rank test). In
contrast, free pNeuECD + CFA showed no signiﬁcant
diﬀerence in time to tumor formation compared with
empty Vir (p<1.5). As shown in Fig. 4a, all mice
developed tumors within 26 days after tumor cell
injection, independent of the vaccine used.
We further investigated the progression of tumor
volume in mice with diﬀerent vaccinations. As shown in
Fig. 4b, there was no signiﬁcant diﬀerence in the tumor
volume 14 days after ﬁrst detection of tumor formation
in mice vaccinated with the diﬀerent Vir-pNeuECD con-
structs. The tumor progression and tumor volumes were
not diﬀerent between the groups either vaccinated with
the diﬀerent Vir-pNeuECD, rVV-NeuECD (two mice
Fig. 3 a rNeu-speciﬁc CTL
activity in mice vaccinated with
diﬀerent DNA-based vaccines.
Mice were vaccinated/boosted
with the indicated vaccines:
WT-VV i.p. (solid diamond),
rVV-NeuECD i.p. (solid square),
fDNA s.c. (solid circle), fDNA-
NeuECD s.c. (shaded open
square), or Vir-DNA-NeuECD
i.p. (solid triangle); 2–5 weeks
after the second vaccination,
spleens were removed, and CTL
activity was assessed in an
XTT-based assay using IT22
and IT22-neu as target cells.
Similar results were seen in four
independent experiments.
b Humoral immune response in
mice vaccinated with diﬀerent
DNA vectors. Mice were
vaccinated and boosted with the
indicated vaccines, and sera
were collected 6 weeks after the
ﬁrst vaccination. NF9006 cells
were incubated with a 1:50
dilution of serum, followed by
REP-conjugated MAbs speciﬁc
for mouse IgG and analyzed for
ﬂuorescence by FACScan. The
mean and standard error of the
mean of each group are shown
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Fig. 4 a Eﬀect of prophylactic
vaccination on time to tumor
formation. All mice develop
tumors within the same time
range after tumor cell injection.
FvB/N mice were vaccinated
and boosted with rVV-NeuECD
i.p. (solid circle), Vir-
pNeuECDenc i.p. (open triangle),
Vir-pNeuECDmem i.p. (open
square), Vir-pNeuECDenc/mem
i.p. (open diamond), free
pNeuECD + adjuvant s.c.(solid
triangle), or empty Vir i.p. (solid
square). The time from tumor
injection to development of
palpable tumors was assessed
every 3 days. Nine to 15 mice
per group were compared.
Statistical analysis using the
Mann-Whitney rank test was
performed. b The eﬀect of the
indicated vaccines on tumor
progression. Tumor volume
was measured every 3 days with
Vernier calibers. Tumor volume
was calculated using the
formula (p/6) · (largest
diameter) · (smallest
diameter)2. Shown are the
combined results of three
independent experiments with
ﬁve mice per group. Bars
represent SEM. Statistical
analysis using the ANOVA
rank test was performed
Table 2 Vaccination with virosome protein prevents tumor for-
mation. Mice were vaccinated and boosted with rVV-NeuECDi.p.,
pNeuECDenc i.p., pNeuECDmem i.p., pNeuECDenc/mem i.p., emptyVir
i.p., or free pNeuECD. Two weeks after the boost, each group was
challenged s.c. with either 0.5·106 Neu+ tumor cells (NF9006) or
0.5·106 Neu tumor cells (K635), and tumor progression was
monitored at the challenge site for 8 weeks. The results combine
three independent experiments
Vaccination Tumor incidence
With rNeu+ challenge With rNeu challenge
rVV-NeuECD 2/13 (15%) 5/7 (71%)
Vir-pNeuECDenc 4/10 (40%) 5/5 (100%)
Vir-pNeuECDmem 3/11 (27%) 5/5 (100%)
Vir-pNeuECDenc/mem 3/10 (30%) 5/5 (100%)
Empty Vir 9/9 (100%) 3/3 (100%)
Free pNeuECD 10/15 (67%) 5/5 (100%)
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developed tumors), or empty Vir (nine mice developed
tumors). These results suggest that Vir-pNeuECD is an
eﬀective vaccine for tumor rejection; however, once the
tumor has formed there was no inﬂuence on tumor
progression.
Induction of both CTL and humoral immune response
in Vir-pNeuECD vaccinated mice
Previous studies have demonstrated that the immu-
nopotentiating eﬀect of modiﬁed reconstituted
Fig. 5 a Neu-speciﬁc CTL
activity in mice vaccinated with
diﬀerent protein-based
vaccines. Mice were vaccinated/
boosted with the following
vaccines: rVV-NeuECD i.p.
(solid circle), Vir-pNeuECD enc
i.p. (open triangle), Vir-pNeuECD
mem i.p. (open square), free
pNeuECD + CFA s.c.(solid
triangle), or empty Vir i.p.(solid
square). Two to ﬁve weeks after
the second vaccination, spleens
were removed, and CTL
activity was assessed in an
XTT-based assay using IT22
and IT22-neu as target cells.
The results of one
representative experiment are
shown. b Humoral immune
response in mice vaccinated
with diﬀerent protein vectors.
IgG ELISA titers in sera (1:25
dilution) from mice after
immunization with rVV-
NeuCD, diﬀerent virosomal
preparations containing
pNeuECD, free pNeuECD, and
empty virosomes. Negative
control mouse sera showed
OD450 nm values between 0.07
and 0.10. Single points
represent the mean values of
triplicate determinations. The
mean and standard error of the
mean of each group are shown
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virosomes induced a cellular immune response [14, 25].
To demonstrate whether immunization with diﬀerent
Vir-pNeuECD constructs was capable of inducing rNeu-
speciﬁc CTL responses, splenocytes were isolated
7 days after booster injection and neu-speciﬁc cytotoxic
activity was investigated against IT22-neu/IT22 cells.
The data depicted in Fig. 5a indicated that mice
immunized with Vir-pNeuECDenc or Vir-pNeuECDmem
developed equally eﬀective rNeu-speciﬁc killing in vitro
at diﬀerent eﬀector to target ratios. Importantly, there
was no diﬀerence in the CTL activity from that of mice
vaccinated with rVV-NeuECD. In contrast, mice
immunized with empty Vir showed only background
levels of speciﬁc cell lysis. Consistent with the lack of
tumor rejection, animals vaccinated with free pNeuECD
+ CFA showed signiﬁcantly lower CTL activity.
To examine whether pNeuECD, either in the mem-
brane or encapsulated in virosomes, could also induce
anti-rNeu Abs, sera of vaccinated and boosted mice
were collected 49–56 days after the ﬁrst vaccination.
The presence of anti-rNeu Abs was assessed by ﬂow
cytometry [23]. Whereas high levels of rNeu-speciﬁc
antibodies were detected in sera from mice injected
with rVV-NeuECD, no rNeu-speciﬁc IgG was detected
in sera of Vir-pNeuECD primed mice. Since pNeuECD was
expressed and produced in E. coli and therefore un-
glycosylated, the induced Abs may only recognize the
protein backbone. Thus, we developed an ELISA using
the same unglycosylated pNeuECD coated to plates as
was used in the virosomal vaccine constructs. Anti-
rNeu Abs were now detected in sera of animals
immunized with Vir-pNeuECDenc, Vir-pNeuECDmem, or
a combination of both and free pNeuECD. In contrast,
animals vaccinated with rVV-NeuECD did not develop
Abs recognizing the unglycosylated form of pNeuECD in
this ELISA. Empty virosomes did not show a rNeu-
speciﬁc humoral response in either of both systems.
Taken together we showed that immunization with Vir-
pNeuECD constructs induced a pNeuECD-speciﬁc cyto-
toxic and humoral immune response that correlated
with tumor rejection.
Discussion
HER-2/neu is an antigen currently being evaluated as a
target for antitumor immunotherapy. Although HER-2/
neu is constitutively expressed at low levels on diﬀerent
normal adult tissues, humoral and cellular immunity
have been shown in patients with HER-2/neu overex-
pressing tumors [5, 6]. Whereas this immunity is clearly
not suﬃcient to provide patients with protection against
malignant tumors, priming or boosting a preexisting
immunity may have therapeutic eﬀects [26, 27]. The
development of new vaccines targeting HER-2/neu and
designed to generate an immune response capable of
rejecting cancer is still needed.
The delivery of the full-length HER-2/neu oncogene
as a vaccine raises signiﬁcant safety issues in patient
treatment. The cytoplasmic domain of HER-2/neu
exhibits a high constitutive tyrosine kinase activity, and
overexpression of this oncogene on cells expressing
other members of the epidermal growth factor receptor
family could trigger the malignant transformation of
infected cells [28]. In some cancer patients humoral
and/or cellular immune responses against the extracel-
lular part of HER-2/neu have been detected [29]. The
relevance of the extracellular domain of HER-2/neu as
immunogen was tested in strategies using DNA vac-
cines [30–32]. Repeated intramuscular injection of
plasmid DNA encoding rNeuECD provided intermedi-
ate levels of protection against a challenge with tumor
cells in mice. Although complete protection was not
observed with plasmid DNA, no striking diﬀerence in
tumor rejection was obtained when plasmid vectors
encoding the full-length rNeu protein (Neu), the rNeu
extracellular and transmembrane (NeuTM) domain, or
the rNeu extracellular (NeuECD) domain were used [30].
Our results supported these reports, showing that
DNA-NeuECD could be used as vaccine and induce an
eﬀective tumor rejection combined with a humoral and
cytotoxic immune response in a preclinical mouse
model.
To improve the immune response and direct fDNA-
NeuECD to the cytoplasma of APCs, we used virosomes
as carrier system. Virosomes are reconstituted from
inﬂuenza virus envelopes and use the same cell receptor–
mediated endocytosis as its viral counterpart [10]. The
receptor binding and the membrane fusion activity of
inﬂuenza virus with endosomes are known to be medi-
ated by the major viral envelope glycoprotein HA [11,
33]. Similar to viral vectors the mildly acidic pH in the
lumen of endosomes triggers the fusion of virosomal
with endosomal membranes and thus the release of
encapsulated material such as DNA, RNA, or proteins
into the cytosol of APCs. Therefore, exogenous in
virosomes encapsulated antigens may access the MHC
class I pathway without the need of de novo protein
synthesis [11, 12, 14, 34]. Not all virosomes are likely to
fuse with endosomal membranes, and therefore a frac-
tion will become available for the MHC class II path-
way. In the current study, we showed that DNA with
virosomes as carrier system penetrated cells and induced
protein expression in vitro. In contrast to previous re-
ports, where intranasal DNA vaccines associated with
virosomes were applied and induced a humoral and CTL
response, Vir-DNA-NeuECD in our model showed nei-
ther CTL nor humoral immune responses or tumor
rejection [14, 34]. Whether the diﬀerence between these
reports and our present study was only based on meth-
ods of application of the vaccine, on diﬀerent vaccina-
tion strategy (priming by inﬂuenza virus), or on a
diﬀerent virosomal carrier system using Escheriagen
(E. coli heat-labile toxin) as adjuvant is still an open
question. Whereas in vitro 20–30% of the cells trans-
fected with Vir-DNA-NeuECD expressed the protein,
vaccination with Vir-DNA-NeuECD in vivo failed to
induce an immune response and tumor rejection, in
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contrast to what was observed after administration of
fDNA-NeuECD.
In humans, immunization strategies using peptides or
peptide-pulsed dendritic cells have been shown to be
eﬀective at priming naive T cells against these peptides
and proteins derived from TAAgs; however, these
strategies have yet to show clinical eﬃcacy [35].
For HER-2/neu, several immunodominant peptides
have been identiﬁed, including a CTL epitope, E75
(spanning amino acids 369–377), that led to the devel-
opment of a peptide-based vaccine for clinical applica-
tions [36–38]. One of these peptides (E75) was tested in a
clinical setting as vaccine and was able to break toler-
ance and generate an anti-HER-2/neu CTL response in
patients [39, 40]. Whereas these T cells easily recognized
peptide-pulsed tumor cells, they failed to recognize and
lyse HER-2/neu-expressing tumor cells, raising the
question whether peptide-based vaccines may induce
peptide-speciﬁc but not native protein-speciﬁc immune
responses. Furthermore, drawbacks of synthetic pep-
tides vaccines are their limited application due to the
restriction of HLA-A2.1 epitopes in clinical indication,
and their lack of standardized methods to immunize
patients.
To avoid the restriction of immunodominant epi-
topes, as well as to generate durable immunity with
putative T-helper epitopes, vaccines using the extracel-
lular domain of HER-2/neu protein (pNeuECD) were
investigated. Immunization of rats with human pNeuECD
in CFA did elicit an immune response to the rat HER-2/
neu antigen (rNeu) but did not protect against tumor
formation of rNeu-expressing tumors [41]. The same
lack of antitumor response was seen in mice vaccinated
with human pNeuECD using montaide 720 as an immu-
noadjuvant [42]. Along the same lines, plasmid DNA
vaccines encoding for the human extracellular domain of
HER-2/neu did induce only a partial or no protection
from a challenge with human HER-2–expressing tumors
[30, 42].
Bearing all these concerns in mind, we investigated
the potential of virosomes as an improved protein
carrier system and immunoadjuvant in cancer vaccines.
Commercially available virosomal vaccines (INFLEX-
AL V, EPAXAL) have been shown to be very eﬃca-
cious and safe [43, 44]. The potential of virosomes as
delivery system has been demonstrated for nucleic
acids and peptide-based vaccines, e.g., for malaria [45].
Recent reports also concluded that synthetic peptide
vaccines administrated s.c. with virosomes were able to
induce a strong CTL immunity [25]. Therefore viro-
somes are expected to generate a strong B-cell and T-
cell immune response [9]. In this report, we demon-
strated that vaccination of mice with pNeuECD +
adjuvant showed tumor rejection in only a few animals
and almost no CTL activity, even when tested at dif-
ferent concentrations of the protein (data not shown).
The immunogenic eﬀect of pNeuECD was signiﬁcantly
increased when the protein antigen was linked to
virosomes, either encapsulated as a soluble protein or
bound to the virosomal membrane. Our results indi-
cated that virosomes are a highly suitable carrier sys-
tem for protein antigens, but did not allow any
conclusions whether there is a higher eﬃciency in
protein linked to the virosomal membrane versus its
encapsulation. However, we did not observed a
complete protection from tumor formation with Vir-
pNeuECD. One reason could be the nature of the pro-
tein antigen. We used unglycosylated proteins pro-
duced by E. coli, that did not correspond to the TAAg
presented by the tumor cells. To further improve the
vaccine, one could use proteins produced by eucaryotic
cells with similar posttranslation modiﬁcations. Fur-
thermore, we did not optimize the eﬃcacy of protec-
tive immunity by changing the injection regimen. As a
last alternative, the route of immunization may further
improve our virosomal vaccination. In our study we
noticed the strongest tumor rejection when virosomes
were injected i.p.
Taken together our results show that virosomes are a
highly suitable carrier system for the delivery of proteins
into the cytosol of APCs and therefore eﬀectively stim-
ulate a cellular and humoral immune response and tu-
mor rejection. Furthermore, the application of truncated
proteins may avoid patient-speciﬁc and HLA-restricted
peptide vaccines. This model is providing important
preclinical data necessary for designing human vacci-
nation trials after primary surgical treatment, either as a
primary vaccination or as a boost in combination with
other vaccines in a context of an adjuvant treatment
plan.
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